CSIMarket
 


Psychemedics Corp  (PMD)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

PMD's Capital Expenditures Growth by Quarter and Year

Psychemedics's Capital Expenditures results by quarter and year




PMD Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.02 0.03 0.00
III Quarter September 0.04 0.09 0.07 0.25
II Quarter June 0.06 0.03 0.03 0.34
I Quarter March 0.04 0.04 0.06 0.47
FY   0.14 0.18 0.19 1.06



PMD Capital Expenditures third quarter 2023 Y/Y Growth Comment
Psychemedics Corp reported drop in Capital Expenditures in the third quarter 2023 by -61.11% to $ 0.04 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Psychemedics Corp's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures growth of 3.84%.

Looking into third quarter 2023 results within Medical Laboratories industry 19 other companies have achieved higher Capital Expenditures growth. While Psychemedics Corp' s Capital Expenditures meltdown of -61.11% ranks overall at the positon no. 2217 in the third quarter 2023.




PMD Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -33.33 % - -
III Quarter September -61.11 % 28.57 % -72 % -67.53 %
II Quarter June 100 % 0 % -91.18 % 47.83 %
I Quarter March 0 % -33.33 % -87.23 % 261.54 %
FY   - -5.26 % -82.08 % -39.08 %

Financial Statements
Psychemedics's third quarter 2023 Capital Expenditures $ 0.04 millions PMD's Income Statement
Psychemedics's third quarter 2022 Capital Expenditures $ 0.09 millions Quarterly PMD's Income Statement
New: More PMD's historic Capital Expenditures Growth >>


PMD Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -77.78 % -57.14 % -
III Quarter September -41.67 % 200 % 133.33 % -26.47 %
II Quarter June 50 % -25 % -50 % -27.66 %
I Quarter March 100 % 33.33 % - -22.95 %
FY (Year on Year)   - -5.26 % -82.08 % -39.08 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #20
Healthcare Sector #342
Overall #2217

Capital Expenditures Y/Y Growth Statistics
High Average Low
264.06 % 3.84 % -100 %
(Mar 31 2020)   (Dec 31 2020)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #20
Healthcare Sector #342
Overall #2217
Capital Expenditures Y/Y Growth Statistics
High Average Low
264.06 % 3.84 % -100 %
(Mar 31 2020)   (Dec 31 2020)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Psychemedics's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
630.2 % 26.9 % -100 %
(Jun 30 2015)  


PMD's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Psychemedics Corp reported fall in Capital Expenditures from the second quarter by -41.67% to $ 0.04 millions, from $ 0.06 millions released in the previous reporting period.

Although periodic influence usually energize III. Quarter 2023 performance, it plainly has not been enough to salvage Psychemedics's outcome, James  Walker, Medical Laboratories industry observer from Liverpool pointed out and mentioned that average quarter on quarter Capital Expenditures growth is at 26.9% for Psychemedics.

Within Medical Laboratories industry 22 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Psychemedics's Capital Expenditures growth quarter on quarter, overall rank is 2331.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #370
Overall #2331
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #370
Overall #2331
Capital Expenditures Q/Q Growth Statistics
High Average Low
630.2 % 26.9 % -100 %
(Jun 30 2015)  


PMD's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Psychemedics Corp realized fall in Capital Expenditures from the previous quarter by -41.67% to $ 0.04 millions, from $ 0.06 millions declared in the previous reporting period.

Even seasonal circumstance which usually fuel III. Quarter 2023 results, it simply has not been substantial to rescue Medical Laboratories's company outcome, James  Walker, Medical Laboratories industry observer from Liverpool pointed out.

Within Medical Laboratories industry 22 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Psychemedics's Capital Expenditures growth quarter on quarter, overall rank is 2331.


Psychemedics's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.16 $ 0.21 $ 0.19 $ 0.19 $ 0.19
Y / Y Capital Expenditures Growth (TTM) -19.17 % 24.71 % 11.45 % 2.75 % 124.42 %
Year on Year Capital Expenditures Growth Overall Ranking # 193 # 1692 # 1904 # 2173 # 294
Seqeuential Capital Expenditures Change (TTM) -26.42 % 14.59 % -1.07 % -3.11 % 13.53 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 988 # 1412 # 1388 # 299 # 639




Cumulative Capital Expenditures growth Comment
For the 12 months ended Sep 30 2023 Psychemedics reported a fall in Capital Expenditures by -19.17% year on year, to $0 millions, compare to the 24.71% growth at Jun 30 2023.

In the Healthcare sector 43 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 193, from total ranking in previous quarter at 1692.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
304.14 %
2.09 %
-113.73 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 10
Healthcare Sector # 44
Overall # 193

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
304.14 %
2.09 %
-113.73 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 137
S&P 500 # 988
Cumulative Capital Expenditures growth Comment
For the 12 months ended Sep 30 2023 Psychemedics reported a fall in Capital Expenditures by -19.17% year on year, to $0 millions, compare to the 24.71% growth at Jun 30 2023.

In the Healthcare sector 43 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 193, from total ranking in previous quarter at 1692.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
304.14 %
2.09 %
-113.73 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 10
Healthcare Sector # 44
Overall # 193

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
304.14 %
2.09 %
-113.73 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 137
S&P 500 # 988




Other Capital Expenditures Growth
Medical Laboratories Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
PMD's Capital Expenditures Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for PMD's Competitors
Capital Expenditures Growth for Psychemedics's Suppliers
Capital Expenditures Growth for PMD's Customers

You may also want to know
PMD's Annual Growth Rates PMD's Profitability Ratios PMD's Asset Turnover Ratio PMD's Dividend Growth
PMD's Roe PMD's Valuation Ratios PMD's Financial Strength Ratios PMD's Dividend Payout Ratio
PMD's Roa PMD's Inventory Turnover Ratio PMD's Growth Rates PMD's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com